Voices of Oncology is a groundbreaking exploration of the evolving landscape in cancer treatment development.
Voices of Oncology is a groundbreaking exploration of the evolving landscape in cancer treatment development. Beyond scientific advancements, the field is being reshaped by societal and cultural forces that are redefining what it takes to bring new therapies to patients.
Through exclusive interviews with leading experts from across oncology, this book captures the complexity of a multidisciplinary approach. Each chapter highlights the challenges and breakthroughs that arise from collaboration between pharmaceutical leaders, academic researchers, patient advocates, and healthcare innovators. Together, these voices underscore a powerful message: only by breaking down silos and sharing insights can we accelerate progress and ultimately, conquer cancer.
To go beyond the book and be a voice in a dynamic collaboration of stakeholders in oncology today, we invite you to join the Oncology Voice Network (OVN), an online community for those committed to transforming oncology through shared knowledge and collective action.
Foreword
Introduction: Increased Understanding = Increased Collaboration
Voice of Academic Clinical Investigation
Voice of Executive Leadership
Voice of Chemistry, Manufacturing, and Controls (CMC)
Voice of Clinical Development
Voice of Commercial
Voice of Compliance
Voice of Health Economics and Outcomes Research and Real-World Evidence
Voice of Innovation Partners
Voice of Market Access
Voice of Medical Affairs
Voice of Field Medical
Voice of National Comprehensive Cancer Network (NCCN)
Voice of the Patient
Voice of Patient Advocacy
Voice of Preclinical Research
Voice of Regulatory Affairs
Voice of Safety
Voice of Scientific Communications
Voice of Statistics in Clinical Research/Biostatistics
Voice of Talent and Workforce Innovation
Voice of Digital and Technology
Conclusion: A Global Hub for Collaboration and Progress
Glossary
Dr. KIRK SHEPARD , a board-certified oncologist and hematologist, has led pharmaceutical innovation for over thirty years, including roles at Boehringer Ingelheim, Takeda, and Eisai. Currently CMO at PDS Biotechnology, his expertise spans all phases of drug development and commercialization. In 2015, PharmaVoice named him among the 100 Most Inspiring People in Pharma. He also cofounded the Medical Affairs Professional Society (MAPS) and co-edited Medical Affairs (2024).
Dr. RAMIN FARHOOD, senior VP at SSI Strategy, has over twenty-five years in patient-centric medical strategy. Previously at Novartis, he launched the worlds first gene therapy for spinal muscular atrophy. Farhood cofounded the Medical Affairs Professional Society (MAPS) and the Immunoglobulin National Society (IgNS) and cohosts The Emerging Biotech Leader podcast.
